582 related articles for article (PubMed ID: 34278578)
1. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
2. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
3. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
[TBL] [Abstract][Full Text] [Related]
4. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
[TBL] [Abstract][Full Text] [Related]
5. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis.
Liu C; Zhou W; Sun X; Zhang X; Xiao H; Yang H; Lin H; Lu Y; Liu Z; Qiu W; Kermode AG; Yang X; Wang Y
Mult Scler Relat Disord; 2024 May; 85():105478. PubMed ID: 38457885
[TBL] [Abstract][Full Text] [Related]
6. High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders.
Liu C; Zhao L; Fan P; Ko H; Au C; Ng A; Au L; Wong A; Kermode AG; Mok V; Yan Y; Qiu W; Lau AY
J Clin Neurosci; 2021 Jan; 83():108-111. PubMed ID: 33317883
[TBL] [Abstract][Full Text] [Related]
7. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa.
Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R
Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595
[TBL] [Abstract][Full Text] [Related]
8. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG
Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341
[TBL] [Abstract][Full Text] [Related]
9. Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder.
Kim H; Kim HJ; So J; Kim JY; Jung HJ; Kim S; Seo D; Kim HJ; Song HE; Lim YM; Yoo HJ; Lee EJ
Mult Scler Relat Disord; 2024 May; 85():105551. PubMed ID: 38564996
[TBL] [Abstract][Full Text] [Related]
10. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
[TBL] [Abstract][Full Text] [Related]
11. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein.
Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219
[TBL] [Abstract][Full Text] [Related]
12. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
[TBL] [Abstract][Full Text] [Related]
13. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
Li Y; Liu Y; Zhao W; An X; Zhang F; Zhang TX; Liu Y; Du C; Zeng P; Yuan M; Zhang N; Zhang C
J Neuroimmunol; 2023 Nov; 384():578218. PubMed ID: 37801952
[TBL] [Abstract][Full Text] [Related]
14. The association of menopausal hormone levels with progression-related biomarkers in multiple sclerosis.
Juutinen L; Ahinko K; Hagman S; Basnyat P; Jääskeläinen O; Herukka SK; Sumelahti ML
Mult Scler Relat Disord; 2024 May; 85():105517. PubMed ID: 38442501
[TBL] [Abstract][Full Text] [Related]
15. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
[TBL] [Abstract][Full Text] [Related]
16. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis.
Thebault S; Lee H; Bose G; Tessier D; Abdoli M; Bowman M; Berard J; Walker L; Rush CA; MacLean H; Booth RA; Narayanan S; Arnold DL; Tabard-Cossa V; Atkins HL; Bar-Or A; Freedman MS
Ann Clin Transl Neurol; 2020 May; 7(5):767-775. PubMed ID: 32304358
[TBL] [Abstract][Full Text] [Related]
17. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
[TBL] [Abstract][Full Text] [Related]
18. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC;
Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534
[TBL] [Abstract][Full Text] [Related]
19. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
Lee EJ; Lim YM; Kim S; Choi L; Kim H; Kim K; Kim HW; Lee JS; Kim KK
Ann Clin Transl Neurol; 2020 Jun; 7(6):992-1001. PubMed ID: 32495489
[TBL] [Abstract][Full Text] [Related]
20. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease.
Kim H; Lee EJ; Kim S; Choi LK; Kim K; Kim HW; Kim KK; Lim YM
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32184342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
